Our Latest News

[NEWS] – Biofortis obtains ANSM authorization and strengthens its position in the development of microbiota-derived therapies

Biofortis announces that it has obtained authorization from the French National Agency for the Safety of Medicines and Health Products (ANSM) for its activities involving the collection of human stool samples intended for the preparation of fecal microbiota for...

Perform a user experience study under expert control

Feb 6, 2024 | News

What is a user experience study? As a clinical research expert, Biofortis can also conduct other types of studies,...

Biofortis will be present at PROBIOTA 2024 – Supporter level sponsor

Jan 10, 2024 | News, Non classé

Feb. 7th to 9th, 2024in Milan, ITALYCome and meet us at PROBIOTA in Milan, Italy.Probiota 2024, the leading Microbiome...

[EVENT] Biofortis will be present at FIE

Oct 30, 2023 | News

Nov. 28th to 30th, 2023in Frankfurt, GERMANYCome and meet us at Food Ingredients Europe (FIE) in Frankfurt, Germany.Fi...

[EVENT] Biofortis will be present at Outsourcing In Clinical Trials Europe 2022

Apr 14, 2022

May 4th and 5th 2022Come and meet us at the Outsourcing In Clinical Trials (OCT) Europe 2022 in Barcelona, Spain. ...

[EVENT] – Biofortis will be present at PHARMABIOTICS 2022

Apr 5, 2022

For this 2022 edition, Biofortis will be present during the Pharmabiotic Research Institute (PRI)'s annual conference...

[EVENT] – Biofortis will be present at Vitafoods Europe 2022

Apr 4, 2022

For this 2022 edition, Vitafoods Europe 2022 will take a hybrid format: we will be present both virtual and in person,...

Innovation Sponsor – MDD 2022

Jan 5, 2022

6th Microbiome Movement Drug Development Europe 2022 January, 26th-27th Come and e-meet us at the 6th Microbiome...

[EVENT] – Biofortis will exhibit at VITAFOODS 2021

Aug 9, 2021

For this 2021 edition, Vitafoods Europe 2021 will take a hybrid format: we will be present both virtual and in person,...

Biofortis continues its development alongside Institut Mérieux

Jul 5, 2021

Benoît Fouchaq, CEO of Biofortis SASAs part of a new strategy, Mérieux NutriSciences has decided to sell the majority...

Explore

our success stories

Case Studies

Contact

our team

Get in touch

Discover

our capabilities

Services